Amesite Inc

Aktienanalyse zu Amesite Inc (AMST)

$0.515

-0.021 (-4.15%)Zum Schluss

Loading chart…
Hoch
0.537
Eröffnung
0.537
Volumengewichteter Durchschnittskurs
0.52
Volumen
24.47K
Marktkap.
7.04M
Tief
0.515
Umsatz
12.79K
EV/EBITDA, TTM
0.00

Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers.

amesite.com

KI-Analyse of Amesite Inc (AMST)

Verkaufen

Amesite Inc is not a good buy right now due to its extremely low Relative Strength Index (RSI) of 11.041, indicating it is oversold, and a staggering year-to-date change of -74.25%, reflecting significant declines in its stock price. The company's financials show consistent net losses, with the latest EPS reported at -0.14 and a forward P/E ratio of 0, suggesting no expected profitability in the near future. The main risk is the substantial decline in stock value, with a 52-week low of 0.52, which indicates a lack of investor confidence and potential for further losses.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Amesite Inc (AMST) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.94.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
-2.94
Aktuelles P/E
0.00
Überbewertet
5.76
Unterbewertet
-11.63

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-3.91
Aktuelles EV/EBITDA
0.00
Überbewertet
17.01
Unterbewertet
-24.83

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
1.59
Aktuelles P/S
0.00
Überbewertet
4.22
Unterbewertet
-1.04

Event-Zeitleiste

2026-09-24 (ET)

07:00:00

Amesite Launches New Sales Model, NurseMagic Enterprise Priced at $1,099 per Month

2026-05-12 (ET)

17:30:00

Amesite Files Prospectus for Resale of 4.84M Shares

2026-04-27 (ET)

12:40:00

Amesite Issues 696,866 Shares at $1.435 Each

11:20:00

X-energy and Yesway Show Strong Debut Performance

09:40:00

Amesite Files for Withdrawal of S-1 Registration Statement

News

AMST FAQ – beantwortet von Alphio AI

Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers. It operates in the Technology sector (SERVICES-PREPACKAGED SOFTWARE industry).

Amesite Inc is not a good buy right now due to its extremely low Relative Strength Index (RSI) of 11.041, indicating it is oversold, and a staggering year-to-date change of -74.25%, reflecting significant declines in its stock price. The company's financials show consistent net losses, with the latest EPS reported at -0.14 and a forward P/E ratio of 0, suggesting no expected profitability in the near future. The main risk is the substantial decline in stock value, with a 52-week low of 0.52, which indicates a lack of investor confidence and potential for further losses.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln